My take is this is seperate to the SubB2M program. EXO-NET is a platform technology used for isolating the relevant exosomes from the sample in question i.e., blood sample from a potential / suspected ovarian cancer patient. The assay UQ will be develop will to detect the relevant exosome marker in question.
Please also note that releasing news of signing a CRO for the SubB2M program is also no guarantee. Will they tech transfer a test developed in the iNOVIQ lab (ELISA / IHC) and if so, optimisation, validation and test readiness under a NATA / CAP accredited lab will need to be completed in roughly 12 - 18 months if we are to see an LDT launch in 2023. Importantly, are they manufacturing a research grade SubB2M product in the meantime in order to provide to the CRO to test in the developed assay?
Ann: INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test, page-19
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
0.005(0.92%) |
Mkt cap ! $60.92M | |||
| Open | High | Low | Value | Volume |
| 56.5¢ | 56.5¢ | 55.0¢ | $15.12K | 26.91K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 13918 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 56.0¢ | 15000 | 1 |
View Market Depth
| Last trade - 15.16pm 06/09/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |